Literature DB >> 16879113

Development of microvascular complications in type 1 diabetic patients 10 years follow-up.

Indira Kulenovic1, Senija Rasic, Suvad Karcic.   

Abstract

Microvascular diabetic complications are the most common causes of morbidity and mortality of patients with type 1 disease. Diabetic nephropathy is becoming the single most common cause of end stage renal failure, while diabetic retinopathy is the most common cause of blindness in working-age population. The main aim of the study was to evaluate the progression of late microvascular complications in type 1 diabetic patients treated by conventional or intensified insulin regimen over the period of 10 years. We selected a random sample of 32 patients, including 14 males and 18 females, aged 30,6 +/- 11,8 years, with average duration of the disease of 4,8 +/- 3,2 years. They did not show signs of overt diabetic nephropathy, while 5 patients had background retinopathy. All the patients had their fasting and postprandial glycaemia, HbAlc, 24/hour proteinuria, blood pressure, height and weight measured and body mass index calculated (BMI). There was a trend towards increasing values of HbAlc (6.9 +/- 0.8 vs. 7.4 +/- 1.0 %, p < 0.05), fasting glycaemia (6.8 +/- 08 vs. 7.8 +/- 1.2 mmol/l, p < 0.05), postprandial glycaemia (9.2 +/- 1.5 vs. 11.3 +/- 1.9 mmol/l, p <0.01), systolic and diastolic blood pressure values (120.0 +/- 10.8 vs. 128.5 +/- 16.8 mmHg, p<0.05; and 73.4 +/- 8.1 vs. 79.8 +/- 9.8 mmHg, p< 0.05) although no hypertensive patient was diagnosed. There were 11 persons (34.4%) with persistent proteinuria of 200 mg/24 hour or more and significant difference in overall proteinuria in 10 yrs period (121.3 +/- 37.3 vs. 312.8 +/- 109.9 mg/24 h, p< 0.001). Overall, 9 persons (28.1%) were diagnosed with simple, background retinopathy, but 6 of them (18.8%) had signs of proliferative form of the disease. The results indicate significant changes in progression of proteinuria in both groups although retinopathic progression was observed but was not significant in the intensively treated group.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879113      PMCID: PMC7192638          DOI: 10.17305/bjbms.2006.3171

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  8 in total

1.  Retinopathy in diabetes.

Authors:  Donald S Fong; Lloyd Aiello; Thomas W Gardner; George L King; George Blankenship; Jerry D Cavallerano; Fredrick L Ferris; Ronald Klein
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 2.  Management of early diabetic nephropathy.

Authors:  M E Molitch
Journal:  Am J Med       Date:  1997-04       Impact factor: 4.965

3.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

Review 4.  Perspectives on diabetic retinopathy.

Authors:  Lloyd M Aiello
Journal:  Am J Ophthalmol       Date:  2003-07       Impact factor: 5.258

Review 5.  Diabetic retinopathy. Control of systemic factors preserves vision.

Authors:  Michael Colucciello
Journal:  Postgrad Med       Date:  2004-07       Impact factor: 3.840

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Ophthalmology       Date:  1998-10       Impact factor: 12.079

8.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

  8 in total
  1 in total

1.  Vascular endothelial growth factor (VEGF)-related single nucleotide polymorphisms rs10738760 and rs6921438 are not associated with diabetic retinopathy (DR) in Slovenian patients with type 2 diabetes mellitus (T2DM).

Authors:  Rifet Terzić; Ines Cilenšek; Ruda Zorc Pleskovič; Sara Mankoč; Aleksandra Milutinović
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.